What is the Impact Factor of Cardiovascular Therapeutics?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Cardiovascular Therapeutics is 2.80, ranking in quartile Q2 of Web of Science (SCIE).

Is Cardiovascular Therapeutics indexed in Web of Science or Scopus?

Yes, Cardiovascular Therapeutics is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.857 (Q2) and an H-index of 62.

Who publishes Cardiovascular Therapeutics and what is the Article Processing Charge (APC)?

Cardiovascular Therapeutics is published by Wiley-Blackwell Publishing Ltd. The estimated Article Processing Charge (APC) is approximately $3,191 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Cardiovascular Therapeutics?

The official ISO-4 abbreviation of Cardiovascular Therapeutics is "CARDIOVASC. THER" with common acronym "cdr". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q2SCImago #6,229Gold OA

Cardiovascular Therapeutics

Acronym:cdr

•

Abbreviation (ISO):CARDIOVASC. THER

•

Identifier (ISSN):1755-5914(Print)/1755-5922(Online)

•

Publisher:Wiley-Blackwell Publishing Ltd

Official Website Submission Portal Compare

Clarivate IF (2026)

2.8↓ -0.6

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Cardiovascular Therapeutics

WoS Q2

Annual Impact Factor Metric

Current (2026):2.8

Scopus SJR & RankScopus Q2

0.857

#6,229

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

62 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessGold OA

36articles/year

100% Gold OA•80.88% Original Research

Aims & Scope

Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.

Topics Covered (Recognized by AI)

Medicine99.9%Internal medicine87%Biology77.2%Cardiology64.6%Chemistry54.9%Biochemistry52.4%Endocrinology50.8%Pathology49.8%Psychology43.9%Psychiatry41%Surgery36.6%Genetics33.9%Pharmacology30.5%Radiology27.6%Myocardial infarction25.4%Heart failure22.4%Physics22.2%

Primary Research Areas

Medicine Cardiac & Cardiovascular Systems

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

CARDIAC & CARDIOVASCULAR SYSTEMS

Rank101/237

IndexSCIE

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank181/356

IndexSCIE

JCISCIE2026

CARDIAC & CARDIOVASCULAR SYSTEMS

Rank76/237

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank120/356

IndexSCIE

Category	Index	Rank	Quartile
CARDIAC & CARDIOVASCULAR SYSTEMS	JCRSCIE	101/237	Q2
PHARMACOLOGY & PHARMACY	JCRSCIE	181/356	Q3
CARDIAC & CARDIOVASCULAR SYSTEMS	JCISCIE	76/237	Q2
PHARMACOLOGY & PHARMACY	JCISCIE	120/356	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF2.8

Articles / Year74

Total Citations21

2025

IF3.4

Articles / Year66

Total Citations132

2024

IF3.4

Articles / Year36

Total Citations259

2023

IF3.1

Articles / Year34

Total Citations280

2022

IF3.368

Articles / Year68

Total Citations1,179

Year	Impact Factor	Articles / Year	Total Citations
2026	2.8	74	21
2025	3.4	66	132
2024	3.4	36	259
2023	3.1	34	280
2022	3.368	68	1,179
2021	3.023	37	640
2020	2.538	61	1,169
2019	2.315	27	1,120
2018	2.245	65	1,105
2017	—	79	1,175
2016	—	85	1,700
2015	—	68	1,444

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #6,229Scopus Q2SCImago Profile

Scopus Coverage:2008-2026

•

Scopus Broad Areas:MedicinePharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q2

0.857

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

2.83

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,191 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations533

3-Year Documents136

Citable Documents136

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate39.4%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Cardiology and Cardiovascular MedicineQ2

Medicine (miscellaneous)Q2

PharmacologyQ2

Pharmacology (medical)Q2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区CARDIAC & CARDIOVASCULAR SYSTEMS

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Cardiovascular Therapeutics (acronym: cdr, abbr: CARDIOVASC. THER, ISSN: 1755-5914) is a peer-reviewed international scholarly journal in the field of Medicine, published by Wiley-Blackwell Publishing Ltd in United States since 2008. The periodical holds a Journal Impact Factor (JIF) of 2.80, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.857 (Q2), an H-index of 62.

The journal enforces rigorous peer evaluation with a publication frequency of Quarterly, an annual output of approximately 36 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,191 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.